

Attached for your review and consideration are examples of how faculty can disclose certain information on grant applications and RPPRs. While these examples can be used as models, each faculty member must determine what pertinent and relevant information must be contained in a disclosure.

- I. Examples of how to disclose scholars in your lab who are funded by a foreign institution or government, who are and are not working on NIH funded research, for active and pending grants.**

Chinese University of Hong Kong paid the stipends of a University of Pittsburgh-affiliated graduate student and a University of Pittsburgh-affiliated visiting scholar from the Chinese University of Hong Kong who were working in Dr. Doe's laboratory from August 2, 2014 to September 25, 2015 (student) and from October 1, 2016 to September 26, 2017 (visiting scholar). No NIH funding was used to support either of these trainees. Both the student and the visiting scholar contributed work to this NIH-funded project. Several Chinese University of Hong Kong students/postdocs and Chinese University of Hong Kong professors Dr. XX and Dr. XXX, who are paid by Chinese University of Hong Kong, also contributed work to this project.

The China Scholarship Council and Peking University, Beijing, China paid the stipends of five University of Pittsburgh-affiliated visiting scholars from Peking University who worked in Dr. Doe's laboratory separately during the periods of November 1, 2011 to March 8, 2013, May 10, 2014 to September 1, 2015, and November 8, 2017 to November 7, 2018. No financial support was provided by Dr. Doe to these visiting scholars, nor did the visiting scholars work on any NIH-funded projects related to Dr. Doe's past, current, or pending support.

A scholarship from the University of Queensland Hospital in Australia paid the stipend of a University of Pittsburgh-affiliated visiting scholar from the University of Queensland who worked in Dr. Doe's laboratory from August 1, 2017 through July 31, 2018. No financial support was provided by Dr. Doe to this visiting scholar, nor did the visiting scholar work on any NIH-funded projects related to Dr. Doe's past, current, or pending support.

OTHER SUPPORT

Doe, John

Active

R21 AR024677-01 (Jones, Jill)

NIH

Targeting of novel receptors in breast cancer therapy

The primary goal of this study is to investigate the potential roles of HER2 in breast cancer therapy and to investigate the impact of HER2-based combination therapies for treatment of metastatic breast cancer.

Disclosure: Shanghai Jiao Tong University paid the stipend of a University of Pittsburgh-affiliated visiting scholar from Shanghai Jiao Tong University who is working in Dr. Doe's laboratory from February 1, 2018 through January 31, 2019. No financial support was provided by Dr. Doe to this visiting scholar, nor did the visiting scholar work on any projects related to Dr. Doe's current or pending NIH support.

Pending

R01 AR084641-01 (Doe, John; Jones, Jill; Kay, Par)

NIH

Novel role of BRCA genes in breast cancer

The breast cancer genes BRCA1 or BRCA2 significantly increase the risk of developing breast cancer and ovarian cancer. The goal of this study is to investigate mutations in BRCA genes to develop therapeutic targets for cancer treatment and early detection.

Disclosure: (1) University of Montreal paid the stipend of a University of Montreal-affiliated graduate student who was working in the laboratory of Dr. Par Kay, a collaborator of Dr. Doe. No NIH financial support was provided by Dr. Kay to this student. This student, supervised by both Drs. Doe and Kay, generated some preliminary data for this project. (2) The University of Toronto paid the stipend of a University of Pittsburgh-affiliated visiting scholar from the University of Toronto who was working in Dr. Doe's laboratory from March 20, 2017 through March 19, 2018. No NIH financial support was provided by Dr. Doe to this visiting scholar. This visiting scholar contributed work to this project. (3) Several University of Toronto students/postdocs and a University of Toronto professor Dr. Jan Jacobs paid by the University of Toronto have also contributed work to this project.

GC07572315 (Doe, John; Kay, Par)

American Cancer Society/RSG

Genetic Epidemiology of Cancer

The focus of this study is to use families to disentangle the influence of genetics from the environment in breast cancer.

Disclosure: The Nanjing University and the Nanjing-affiliated Hospital paid the stipends of a University of Pittsburgh-affiliated graduate student and a University of Pittsburgh-affiliated visiting scholar from Nanjing University who were working in Dr. Doe's laboratory from August 1, 2015 to July 31, 2016 (student) and from December 1, 2017 to November 30, 2018 (visiting scholar). No financial support was provided by Dr. Doe to either of these trainees. Both the student and the visiting scholar contributed work to this project. Several Nanjing University

students/postdocs and Nanjing University professors Dr. XX and Dr. XXX paid by Nanjing University have also contributed work to this project.

II. Examples of how to disclose PI's collaborative research associated with a grant from a foreign granting institution

72146858

PI: XXX and Doe

07/01/2015 – 06/30/2017

National Natural Science Foundation of China

¥250,000

Title: Role of BRCA-1 and BRCA-2 in breast cancer therapy

(Note: One aim of this project had partial overlap with Dr. Doe's R01AR084641-01. The inhibitors used in this grant were obtained commercially. No new IP resulted from this project, and no IP was transferred from Dr. Doe's research group to Dr. XXX's group. Funds from this grant were administered exclusively in China and only accessible to Dr. XXX. No funds from this grant have been used to support any research activities or personnel in Dr. Doe's lab)

III. Examples of how to disclose PI's startup package.

Start-up Package

Dr. Doe received a start-up package from the University of Pittsburgh. All funds were expended by 2017. No overlap with this project.

BROWN, JILL

Start-up Package

Dr. Brown received a start-up package from the University of Pittsburgh. Funds are currently being expended on this start-up.

Foreign Collaboration

Dr. Brown had collaborations at Trinity College Dublin and Dublin City University, both in Dublin, Ireland, which resulted in several co-authored papers. The collaboration with them was not supported by any funding nor requirement of effort, and they were not on any NIH-funded projects. In 2019, we decided to end these collaborations.
